Bull Case

Dexcom sustains CGM share gains in diabetes and expands into adjacent populations, driving revenue growth above Abbott’s Libre-led pace and supporting operating leverage.

Recent product-cycle execution and sensor reliability improvements reduce churn and reimbursement friction, lifting retention and gross margin versus peers with more commoditized glucose-monitoring offerings.

International penetration and channel expansion accelerate as payer access broadens, allowing Dexcom to compound faster than Medtronic’s smaller CGM base and preserve premium pricing.

Operating margin expands from the low-20% TTM level as scale and mix improve, while modest leverage keeps interest burden negligible and protects free cash flow conversion.

Base Case

Dexcom continues to grow faster than the broader diabetes-device market, but Abbott’s larger installed base and pricing pressure cap share gains and keep growth premium moderate.

Operating profit margin improves to 22.9% TTM from the low-20% range as manufacturing scale offsets ongoing commercial investment, leaving profitability solid but not yet peer-leading.

International and non-diabetes adoption add incremental revenue, yet reimbursement normalization and competitive launches limit upside versus the strongest CGM peers.

Low net debt and high interest coverage preserve financial flexibility, while valuation remains anchored by execution consistency rather than a step-change in margin expansion.

Bear Case

Abbott’s Libre franchise and pricing actions slow Dexcom’s share gains, causing growth to decelerate toward the market and compressing the company’s premium versus peers.

Product or supply execution issues raise churn and reimbursement friction, pressuring sensor utilization and preventing operating leverage from offsetting commercial spending.

International expansion underperforms as payer adoption and channel execution lag, leaving revenue concentration higher than peers with broader global scale.

Margins retreat from the low-20% range while valuation multiple compression follows slower growth, though low leverage limits balance-sheet stress and avoids a severe downside.

Overall Score

Dexcom’s forward profile remains structurally strong versus peers, with the base case anchored by durable CGM growth, solid margins, and limited balance-sheet risk.